




公告日期	2025/10/13
異動類別	藥品變更
異動原因	包裝變更
異動描述	Elotuzumab inj 300mg/12mL/vial (Empliciti[®]) 恩必喜凍晶注射劑廠商來文，自批號8146929起，新增主製造廠/產地「Patheon Italia S.p.A. Monza Operations/Italy」，外包裝製造廠資訊變更，藥品包裝變更。 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	301852	
學名	Elotuzumab	
商品名	Empliciti	
中文名	恩必喜凍晶注射劑	
主成份及含量	300mg/12mL/vial	
製造廠名稱	Bristol-Myers Squibb Holdings Pharma Ltd.,Liability Company (必治妥施貴寶)	
產地	美國	
健保代碼	KC01021266	
外觀/圖檔		
用法	靜脈滴注	
小孩劑量	Safety and effectiveness have not been established in pediatric patients.	
成人劑量	Combination with Lenalidomide and Dexamethasone: 10 mg/kg administered intravenously every week for the first two cycles (28day cycle) and every 2 weeks thereafter. Combination with Pomalidomide and Dexamethasone: 10 mg/kg administered intravenously every week for the first two cycles (28day cycle). Starting at cycle 3,20 mg/kg intravenously every 4 weeks.	
副作用		